Send the following on WhatsApp
Continue to ChatPfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints https://thecitylife.org/2020/11/18/pfizer-and-biontech-conclude-phase-3-study-of-covid-19-vaccine-candidate-meeting-all-primary-efficacy-endpoints/